CORE (research service)

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, May 25, 2023
Exercise, GSK, Interim, Total, AACR, Obesity, Diet, Therapy, Table, Marketing, Culture, CD200R1, Stroke, Tax, Pharmacokinetics, Research, PGS, Consumer service, Sale, EBITDA, Patient, Risk, Novartis, Webcast, Afkhami, Consumer, ESG, Poster, Growth, Adjustment, Gene, Disease, Safety, Pharmaceutical industry, CORE (research service)

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of fiscal year 2023 (FY2023), which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired with billions of phenotypic data points contributed by engaged customers. This unique platform enables the Company to discover new genetic insights, develop impactful risk prediction reports for common health conditions, and accelerate the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • The results showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignancies.
  • The Phase 2a portion of the study will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 25, 2023 to discuss the financial results for the full year and Q4 FY2023 and report on business progress.
  • A webcast replay will be available at the same address for a limited time within 24 hours after the event.

MCI Onehealth Reports Fiscal 2022 Financial Results and Announces Review of Strategic Alternatives

Retrieved on: 
Monday, April 3, 2023
Lincolnshire Co-operative Challenge, NOT, FOR, Face, Bank statement, Committee, COVID-19, Research, MCI, Patient, WIRE, EBITDA, Physician, Nursing, Data, CHS, NEWS, TSX, Select or special committee (United States Congress), News, Polyclinic, CORE (research service), Pharmaceutical industry, Audit, Bank, Bookkeeping, Praise of Bogdiin Khuree

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. (“MCI” or the “Company”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, has released its financial results for the financial year ended December 31, 2022 and announced that it is engaged in a review of strategic alternatives available to the Company.

Key Points: 
  • Financial measures described as “Adjusted” in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies.
  • The Company is also continually evaluating other alternatives of generating cash in the short term, such as disposing of non-core assets.
  • Significant financial and operational highlights for MCI during the fourth quarter of 2022 included:
    Revenue Stable Quarter-over-Quarter: Revenue for Q4 FY22 remained stable over Q4 FY21.
  • As a result, the Company’s Special Committee, comprised of two independent directors, is reviewing and evaluating a range of potential strategic alternatives for the Company.